🚨 Nearly 7 MONTHS longer median survival in endometrial cancer!
#ESMO26 LBA11 | Phase III TroFuse-005
Sacituzumab tirumotecan vs chemotherapy:
🔹 OS: 19.0 vs 12.1 months (HR 0.68)
🔹 PFS: 7.2 vs 3.9 months (HR 0.59)
🔹 ORR: 35.1% vs 17.3%
A potential new standard after platinum + immunotherapy!
@myesmo @ESMO_open @oncoalert
67 views · 1 like · 2 reposts · 0 replies
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgRaludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Updated results from the phase 2 dose-optimization part of REJOICE-Ovarian01
https://esmocongress.esmo.orgIparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase
https://esmocongress.esmo.orgClinical utility of circulating tumor DNA (ctDNA) for participants with resected, high-risk dMMR endometrial cancer (EC) receiving adjuvant treatment: Results from the ENGOT-en11/GOG-3053/KEYNOTE-B21 study
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org🚨 ESMO 2026 | TOP 10 GYNAE ONCOLOGY TRIALS TO WATCH! From chemotherapy-free immunotherapy to next-generation ADCs, #ESMO26 could reshape gynaecological oncology! 🔥 My Top 10, by cancer subtype: 🔴 ENDOMETRIAL CANCER TroFuse-005 (LBA11) | Sacituzumab tirumotecan vs physician’s choice in recurrent/advanced disease. KEYNOTE-C93 (LBA12) | Pembrolizumab alone vs chemotherapy in 1L dMMR disease. Can we omit chemotherapy? NRG-GY020 (1239O) | Adjuvant radiotherapy ± pembrolizumab in early-stage dMMR disease. Sacituzumab tirumotecan + pembrolizumab (1259P) | ADC + immunotherapy in post-platinum pMMR disease. 🔵 OVARIAN CANCER BEHOLD-1 (LBA41) | Mocertatug rezetecan, a B7-H4 ADC, in platinum-resistant disease. REJOICE-Ovarian02 (1247RO) | Raludotatug deruxtecan + bevacizumab in platinum-resistant disease. REJOICE-Ovarian01 (1331P) | Updated efficacy and safety of raludotatug deruxtecan. BEHOLD-1 biomarker analysis (1248RO) | Which biomarkers predict response to B7-H4 ADC therapy? 🟣 CERVICAL CANCER CALLA (LBA45) | Tisotumab vedotin + pembrolizumab vs chemotherapy in recurrent/metastatic disease. EMPOWER-Cervical 1 (1250O) | Cemiplimab-based strategies and long-term outcomes. ⭐ My top 3 to watch: KEYNOTE-C93 | TroFuse-005 | BEHOLD-1 Which trial has the greatest potential to change your practice? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #GynOnc #Oncology在 X 查看被引用的帖子
Source: Dr Rishabh Jain · x.com